COUR Pharmaceuticals Partners with Roche's Genentech for Autoimmune Therapies Deal Over $900M

COUR Pharmaceuticals has partnered with Roche's Genentech to develop innovative therapies for autoimmune diseases, leveraging COUR's antigen-specific immune tolerance platform[1]. This collaboration involves an upfront payment of $40 million from Roche, with future milestone payments potentially exceeding $900 million along with tiered royalties[2]. COUR will oversee preclinical development and manufacturing, whereas Genentech will handle clinical development and commercialization efforts[1][2]. The partnership aims to create disease-modifying therapies that address the root causes of immune-mediated conditions[1].